Updated:
Medmarc Insurance Group
Medmarc Insurance Group was founded in 1979 by the Health Industry Manufacturers Association — AdvaMed's predecessor — to solve a structural gap: conventional...
Medmarc Insurance Group
Medmarc Insurance Group was founded in 1979 by the Health Industry Manufacturers Association — AdvaMed's predecessor — to solve a structural gap: conventional carriers either wouldn't write liability coverage for early-stage medical-device firms or priced it as generic manufacturing risk. Medmarc's sole underwriting focus is life-sciences and medical-technology companies that develop, test, and commercialize regulated healthcare products. The firm's principal, Karen Murphy, runs the day-to-day operation as President of Life Sciences. The firm writes three primary lines: products liability for finished medical devices and diagnostics, clinical-trial liability that protects sponsors and investigators during FDA-regulated studies, and errors-and-omissions for professional services. Medmarc does not behave like a generalist insurer with a side bet on healthcare — its claims, underwriting, and risk-management teams work exclusively with medtech portfolios. The underwriting footprint spans the United States and Canada, with dedicated claims handlers and regional business-development representatives covering all 50 states plus Canadian markets. Medmarc has been a subsidiary of ProAssurance Corporation since ProAssurance acquired it for $153.7 million in 2013. Subsequent corporate moves have redrawn the ownership stack: in May 2026, ProAssurance entered a definitive agreement to be acquired by The Doctors Company, a physician-owned medical-malpractice carrier. The deal puts Medmarc under a parent that is itself deeply specialized in healthcare liability, reinforcing the firm's narrow-service structure rather than diluting it. Medmarc maintains dedicated offices in Chantilly, Virginia; the firm does not disclose total investable assets or professionals count. Structurally, Medmarc differs from most asset-owner peers in this dataset because its capital base is not discretionary wealth — it is statutory policyholder surplus (claims-paying reserves) held inside a regulated insurance entity. The firm does not operate as a family office, a fund manager, or an allocator in the traditional sense. Its "deployment" is premium float; its "portfolio" is the risk book of medtech manufacturers. That architecture makes Medmarc a sector-liquidity provider — it supplies balance-sheet capacity to an industry that conventional markets have historically avoided — rather than an LP or co-investor.
General information
Firm type
Insurance
Year founded
1979
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Chantilly
Corporate office
14280 Park Meadow Drive, Suite 300, Chantilly, VA 20151, United States
Additional offices
4795 Meadow Wood Lane, Suite 335 West, Chantilly, VA 20151-2219
Principals
Karen Murphy
President of Life Sciences
Sector focus
Frequently asked questions
Who runs investment decisions at Medmarc?
Medmarc is a specialty liability insurance carrier, not an asset manager. Its primary capital function is underwriting medical-technology risk, not deploying a discretionary investment portfolio. The firm's President of Life Sciences, Karen Murphy, oversees operations, while investment management of policyholder surplus falls under the parent company, ProAssurance Corporation — which has entered an agreement to be acquired by The Doctors Company (per ProAssurance press release, May 2026).
Is Medmarc structured as a single-family office or an asset manager?
Neither. Medmarc is a regulated property-and-casualty insurance carrier domiciled in the United States, operating as a wholly owned subsidiary of ProAssurance Group. Its capital base is statutory surplus, not family wealth or third-party limited-partner commitments. This structure subjects Medmarc to insurance-department capital requirements, not the redemption or deployment rhythms of a fund vehicle.
How is Medmarc related to ProAssurance?
ProAssurance Corporation acquired Medmarc in 2013 for $153.7 million. Medmarc operates as a separately branded subsidiary within the ProAssurance family of specialty liability carriers. In May 2026, ProAssurance entered a definitive agreement to sell itself to The Doctors Company, which will make Medmarc part of one of the largest physician-owned medical-malpractice insurers in the United States.
What investment stages does Medmarc target?
Medmarc does not target investment stages in the private-capital sense. It underwrites liability insurance for life-sciences companies at every commercial phase — from pre-revenue clinical-trial-stage firms through large publicly traded device manufacturers. This continuum makes Medmarc one of the few carriers willing to write coverage for companies that have no commercial-sales history and are still in FDA-regulated studies.
Which sectors does Medmarc explicitly avoid?
Medmarc's entire charter is built on a sector exclusion: it writes only life-sciences and medical-technology risk. General healthcare services, hospital professional liability, non-medtech manufacturing, and standard commercial-liability lines fall outside its underwriting appetite. Those exposures are handled by sister carriers within ProAssurance or by the market at large.
Does Medmarc maintain philanthropic structures?
Medmarc participates in two giving programs: the Medmarc Give Back Campaign and the broader ProAssurance Foundation. Both are employee-driven; neither functions as a grant-making private foundation with a separate investment portfolio. Financial disclosures for either program are not publicly itemized.
What is Medmarc's known posture on co-investments alongside external GPs?
Medmarc is an insurance underwriter, not a fund investor or co-investor. The firm deploys capital as premium float into a medtech-liability risk book rather than allocating to general partners. Any institutional-investor activity — such as limited-partner commitments — would occur at the ProAssurance parent level, not inside the Medmarc operating subsidiary.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: